| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,343 |
2,855 |
$308K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,796 |
3,278 |
$249K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,737 |
1,549 |
$149K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
642 |
564 |
$81K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
692 |
487 |
$65K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,307 |
1,131 |
$49K |
| 99051 |
|
2,579 |
2,338 |
$17K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
53 |
44 |
$13K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
396 |
278 |
$8K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
397 |
278 |
$8K |
| 99072 |
|
2,695 |
2,336 |
$7K |
| S9088 |
Services provided in an urgent care center (list in addition to code for service) |
4,205 |
3,755 |
$7K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
132 |
107 |
$7K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
109 |
98 |
$6K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
290 |
255 |
$6K |
| 87481 |
|
247 |
175 |
$4K |
| 87529 |
|
129 |
94 |
$4K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
52 |
43 |
$3K |
| 87640 |
|
152 |
105 |
$3K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
131 |
107 |
$2K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
118 |
81 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
833 |
695 |
$2K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
95 |
91 |
$2K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
90 |
86 |
$2K |
| 87486 |
|
56 |
46 |
$1K |
| 87581 |
|
56 |
46 |
$1K |
| 80053 |
Comprehensive metabolic panel |
157 |
127 |
$949.45 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
43 |
38 |
$905.22 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
198 |
161 |
$887.14 |
| 87653 |
|
55 |
37 |
$867.34 |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
19 |
13 |
$617.76 |
| 90756 |
|
23 |
17 |
$501.09 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
32 |
25 |
$389.14 |
| 87500 |
|
19 |
13 |
$333.32 |
| 87511 |
|
13 |
12 |
$221.04 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
14 |
12 |
$218.11 |
| 81003 |
|
137 |
101 |
$162.52 |
| 99000 |
|
703 |
564 |
$122.29 |